NLTX News and Press, Neoleukin Therapeutics Inc. From 08/10/22

The following slide deck was published by Neoleukin Therapeutics, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Neoleukin Therapeutics, Inc. 2022 Q2 - Results - Earnings Call Presentation

Neoleukin Therapeutics, Inc. (NLTX) Q2 2022 Earnings Conference Call August 9, 2022 16:30 ET Company Participants Julie Rathbun - Investor Relations Jonathan Drachman - Chief Executive Officer Priti Patel - Chief Medical Officer Sean Smith - Vice President, F...

SEATTLE, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executi...

SEATTLE, July 27, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin” (NASDAQ:NLTX), today announced it will report second quarter 2022 financial results on Tuesday, August 9, 2022 after the close of financial markets and then host a conference call and live audio webc...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investors in penny stocks know that they are an inherently risky proposition. That goes double for any investor just getting into this market. But with great risk comes great reward. In this case, I think these are penny s...

Baker Brothers’ 13F portfolio value decreased from $20.55B to $17.40B this quarter. Horizon Therapeutics was increased while decreasing Legend Biotech. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to almost 68% of the portfolio. ...

SEATTLE, May 16, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced treatment of the first patient in a combinat...

Neoleukin Therapeutics press release (NASDAQ:NLTX): Q1 GAAP EPS of -$0.28 beats by $0.02. “During the first quarter of 2022 our dedicated team at Neoleukin has been focused on execution of our NL-201 Phase 1 clinical trial, evaluating multiple schedules during dose escalation in patien...

SEATTLE, May 09, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results for the quarter ending Mar...

Shares of Neoleukin Therapeutics (NASDAQ:NLTX) have lost 10.6% in morning trade on Wednesday, despite the company announcing presentation of preclinical data for its immunotherapy candidate NL-201 that highlighted its potential to treat hematologic cancers. The data was presented in a po...